Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Hikma Pharmaceuticals

HKMPYOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$58.00

At close: Jan 17, 9:28 AM EDT

$51.95

-6.05-10.43%

After Hours: Jan 17, 9:28 AM EDT

Hikma Pharmaceuticals (HKMPY) Forecast

News

Earnings Hikma Pharmaceuticals (HKMPY) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Hikma Pharmaceuticals (OTC:HKMPY) Stock

Hikma Pharmaceuticals Stock (OTC: HKMPY)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, September 06, 2024

Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Vandana Singh

Wednesday, August 28, 2024

Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Vandana Singh

Monday, June 12, 2023

Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape
Vandana Singh

Tuesday, March 31, 2020

Amarin Shares Drop 67% As Court Invalidates Its Heart Drug Patent For Vascepa
Neer Varshney

Tuesday, December 10, 2019

Stocks That Hit 52-Week Highs On Tuesday
Lisa Levin

Thursday, April 06, 2017

UBS Likes The Tune Of Jazz Pharma's Settlement With Hikma
Benzinga

Monday, March 20, 2017

Jazz Pharma Gives Shorts A Wake-Up Call After JZP-110 Study Results
Benzinga
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Benzinga

Wednesday, February 10, 2016

Hikma Pharmaceuticals Offering $535M Less than Earlier Offer to Acquire Boehringer Ingelheim's US Generic Drug Business
Benzinga

Wednesday, March 11, 2015

Hikma Pharmaceuticals 2014 Profit Surges
Benzinga

Wednesday, November 20, 2013

Hikma Signs Long Term Supply Agreement With Unilife To Enhance Delivery Of Generic Injectables
Benzinga

Wednesday, March 13, 2013

Hikma Pharma Full-Year Profit Rises 19%
Benzinga

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved